Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells

Biomedicine and Pharmacotherapy

Volumn 63, Issue 4, 2009, Pages 262-266

  Luczak M W ^a   Jagodzinski P P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

CYP19; mRNA; RQ PCR

Indexed keywords

AROMATASE; CELL PROTEIN; ESTROGEN; MESSENGER RNA; PROTEIN SYNTHESIS INHIBITOR; RIBONUCLEASE; TRICHOSTATIN A;

ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; HALF LIFE TIME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HALF-LIFE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; NEOPLASM PROTEINS; RNA STABILITY; RNA, MESSENGER; RNA, NEOPLASM;

EID: 64749116137     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.05.002     Document Type: Article

References (34)

1. Evans C.T., Ledesma D.B., Schulz T.Z., Simpson E.R., and Mendelson C.R. Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. Proc Natl Acad Sci U S A 83 (1986) 6387
2. Harada N. Cloning of a complete cDNA encoding human aromatase: immunochemical identification and sequence analysis. Biochem Biophys Res Commun 156 (1988) 725
3. Harada N., Utsumi T., and Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci U S A 90 (1993) 11312
4. Key T.J., Appleby P.N., Reeves G.K., Roddam A., Dorgan J.F., Longcope C., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95 (2003) 1218
5. Endogenous Hormones and Breast Cancer Collaborative Group. Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomarkers Prev 12 (2003) 1457
6. Henderson B.E., and Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 21 (2000) 427
7. Perel E., Wilkins D., and Killinger D.W. The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J Steroid Biochem 13 (1980) 89
8. Yue W., Wang J.P., Hamilton C.J., Demers L.M., and Santen R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58 (1998) 927
9. Sasano H., Nagura H., Harada N., Goukon Y., and Kimura M. Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum Pathol 25 (1994) 530
10. Sasano H., Suzuki T., Nakata T., and Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 13 (2006) 129
11. Baston E., and Leroux F.R. Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development. Recent Patents Anticancer Drug Discov 2 (2007) 31
12. Richardson B., and Yung R. Role of DNA methylation in the regulation of cell function. J Lab Clin Med 134 (1999) 333
13. Thiagalingam S., Cheng K.H., Lee H.J., Mineva N., Thiagalingam A., and Ponte J.F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983 (2003) 84
14. Luczak M.W., and Jagodzinski P.P. The role of DNA methylation in cancer development. Folia Histochem Cytobiol 44 (2006) 143
15. Vigushin D.M., Ali S., Pace P.E., Mirsaidi N., Ito K., Adcock I., et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7 (2001) 971
16. Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., and Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48 (2001) 20
17. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188
18. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., and Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63 (2003) 7291
19. Piacentini P., Donadelli M., Costanzo C., Moore P.S., Palmieri M., and Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 448 (2006) 797
20. Zhang X., Yashiro M., Ren J., and Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16 (2006) 563
21. Zhou C., Qiu L., Sun Y., Healey S., Wanebo H., Kouttab N., et al. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 29 (2006) 269
22. Chomczynski N., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156
23. Januchowski R., Dabrowski M., Ofori H., and Jagodzinski P.P. Trichostatin A down-regulate DNA methyltransferase 1 in Jurkat T cells. Cancer Lett 246 (2007) 313
24. Xiong Y., Dowdy S.C., Podratz K.C., Jin F., Attewell J.R., Eberhardt N.L., et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res 65 (2005) 2684
25. Zhu W.G., and Otterson G.A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3 (2003) 187
26. + T cell responses. BMC Cancer 3 (2003) 30
27. Januchowski R., and Jagodzinski P.P. Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells. Int Immunopharmacol 7 (2007) 198
28. Kozłowska A., and Jagodziński P.P. Effect of trichostatin A on CD4 surface density in peripheral blood T cells. Folia Histochem Cytobiol 44 (2006) 259
29. Hodges-Gallagher L., Valentine C.D., Bader S.E., and Kushner P.J. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 105 (2007) 297
30. Nelson L.R., and Bulun S.E. Estrogen production and action. J Am Acad Dermatol 45 (2001) S116
31. Bennett R.C. Long term follow-up of surgical adrenalectomy for breast cancer. Aust N Z J Surg 53 (1983) 415
32. Devitt J.E., and Hardwick J.M. Role of bilateral adrenalectomy (and oophorectomy) in the management of patients with metastatic breast cancer. Am J Surg 137 (1979) 629
33. Manni A., Pearson O.H., Brodkey J., and Marshall J.S. Transsphenoidal hypophysectomy in breast cancer: evidence for an individual role of pituitary and gonadal hormones in supporting tumor growth. Cancer 44 (1979) 2330
34. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348 (1996) 1189